Publications by authors named "Giovanni Perri"

Claim this Profile
F
Full reservoirs and poor adherence: two cases of symptomatic HIV cerebrospinal fluid escape with tenofovir alafenamide/emtricitabine/bictegravir.
Andrea Calcagno, Carola Lipani, Barbara Rizzello, Marco Mussa, Andrea Perinzano, Giovanni Di Perri

AIDS· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition.
Mattia Trunfio, Rossana Scutari, Valeria Fox, Elisa Vuaran, Raha Maryam Dastgheyb, Giovanni Di Perri

Front Microbiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extending follow-up visits in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinion.
Giovanni Di Perri, Stefano Bonora

Infez Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort.
Andrea Antinori, Giulia Marchetti, Vincenzo Esposito, Stefano Rusconi, Diana Canetti, Giovanni Di Perri

Int J STD AIDS· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing Gait Analysis: Integrating Multimodal Neuroimaging and Extended Reality Technologies.
Vera Gramigna, Arrigo Palumbo, Giovanni Perri

Bioengineering (Basel)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition.
Mattia Trunfio, Rossana Scutari, Valeria Fox, Elisa Vuaran, Raha Maryam Dastgheyb, Giovanni Di Perri

bioRxiv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How Antiretroviral Drug Concentrations Could Be Affected by Oxidative Stress, Physical Capacities and Genetics: A Focus on Dolutegravir Treated Male PLWH.
Jessica Cusato, Anna Mulasso, Micol Ferrara, Alessandra Manca, Guido Accardo, Giovanni Di Perri

Antioxidants (Basel)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study.
Mattia Trunfio, Elisa Vuaran, Daniela Vai, Caterina Quarta, Alessandro Di Stefano, Giovanni Di Perri

AIDS Behav· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pharmacology of the Single Tablet Regimen Bictegravir/Emtricitabine/Tenofovir Alafenamide in the evolving era of antiretroviral therapies.
Giovanni Di Perri, Stefano Bonora

New Microbiol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial.
Alessandro Lazzaro, Daniela Vai, Ambra Barco, Giacomo Stroffolini, Veronica Pirriatore, Giovanni Di Perri

J Acquir Immune Defic Syndr· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated with HIV Viral Suppression in People Followed in an Outpatient Clinic in Angola During and After the COVID-19 Pandemic.
Andrea Calcagno, Costanza Pizzi, Barbara Pocongo, Niccolò Ronzoni, Francesca Alladio, Giovanni Di Perri

AIDS Patient Care STDS· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central Nervous System Disorders with Auto-Antibodies in People Living with HIV.
Giacomo Stroffolini, Cristiana Atzori, Daniele Imperiale, Mattia Trunfio, Giovanni Di Perri

Microorganisms· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Further considerations on the use of cerebrospinal fluid C-X-C motif chemokine ligand 13 in the diagnosis of neurosyphilis among people with HIV.
Mattia Trunfio, Stefano Bonora, Giovanni di Perri, Andrea Calcagno

AIDS· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Host single nucleotide polymorphisms and biomarkers of neuronal damage and inflammation in people living with HIV.
Jessica Cusato, Alessandra Manca, Alice Palermiti, Jacopo Mula, Valeria Avataneo, Giovanni Di Perri

Int J Antimicrob Agents· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ritonavir: 25 Years' Experience of Concomitant Medication Management. A Narrative Review.
Romina Quercia, Giovanni Di Perri, Carolina Pein, Jennifer Bodie, Ravi Shankar P Singh

Infect Dis Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Studying the Changes in Physical Functioning and Oxidative Stress-Related Molecules in People Living with HIV after Switching from Triple to Dual Therapy.
Jessica Cusato, Anna Mulasso, Micol Ferrara, Alessandra Manca, Miriam Antonucci, Giovanni Di Perri

Antioxidants (Basel)· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrathecal production of anti-Epstein-Barr virus viral capsid antigen IgG is associated with neurocognition and tau proteins in people with HIV.
Mattia Trunfio, Alessandra Sacchi, Daniela Vai, Fabrizia Pittaluga, Michele Croce, Giovanni Di Perri

AIDS· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HBsAg kinetics after 7 years of therapy with tenofovir disoproxil fumarate in a cohort of naïve patients affected by chronic hepatitis B with different genotypes.
Lucio Boglione, Tommaso Lupia, Giacomo Stroffolini, Valentina Dodaro, Giovanni Di Perri

Infect Med (Beijing)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parietal resting-state EEG alpha source connectivity is associated with subcortical white matter lesions in HIV-positive people.
Claudio Babiloni, Claudio Del Percio, Claudia Piervincenzi, Filippo Carducci, Raffaele Ferri, Giovanni Di Perri

Clin Neurophysiol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid Inhibitor.
Giovanni Di Perri

Infez Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pillars of long-term antiretroviral therapy success.
Lucia Taramasso, Massimo Andreoni, Andrea Antinori, Alessandra Bandera, Paolo Bonfanti, Giovanni Di Perri

Pharmacol Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Moti N Ramgopal, Antonella Castagna, Charles Cazanave, Vicens Diaz-Brito, Robin Dretler, Giovanni Di Perri

Lancet HIV· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacology of the SingleTablet Regimen (STR) Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF).
Giovanni Di Perri

Infez Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.
Carlo Torti, Pier Paolo Olimpieri, Paolo Bonfanti, Carlo Tascini, Simone Celant, Giovanni Di Perri

Lancet Reg Health Eur· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review.
Francesco Venuti, Mattia Trunfio, Anne-Grete Martson, Filippo Lipani, Sabrina Audagnotto, Giovanni Di Perri

Drugs· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis